Intravacc uses cookies to record web statistics of visitors to its website. A cookie is a small text file that is stored on your computer to help us
identify you during subsequent visits to our website. Do you accept this?

Slider nummer 1

Meet Intravacc

Intravacc has a long history in developing vaccines. It promotes public health by developing vaccines from the laboratory to clinical study in man. To achieve this mission, our aim is to substantially reduce development risks and costs of new vaccines by bridging the translational gap between laboratory bench and market.

Factsheets

Take a look at our factsheets to discover the variety of our research and development activities. 

View all factsheets

Roadmap on Vaccines

The “Innovation Partnership for a Roadmap on Vaccines in Europe” (IPROVE) has launched on 16 March a strategic roadmap setting out a vision for vaccine research and innovation in Europe. The roadmap will inform strategic decisions on the priorities for future vaccine investment in innovation and technological development at European Union and individual Member State level. Through a bottom-up approach involving all key stakeholders in the European vaccine field, the strategy aims to overcome fragmentation and remove bottlenecks to translation of breakthrough research into innovative vaccines.

Read more...

A sustainable, good, affordable Hib vaccine for every child

With her doctoral research, TU Delft doctoral candidate Ahd Hamidi has made a major contribution to developing an innovative, scalable, affordable version of the Haemophilus influenzae (Hib) vaccine developed by Intravacc. This low-cost vaccine has now been used to protect 200 million children worldwide against Hib diseases such as meningitis, pneumonia, sepsis and otitis media. Hamidi has defended her dissertation at TU Delft on Thursday 3 March.

Read more...

Intravacc teams up with the Viral Pseudotype Unit

Pseudo viruses (PVs) are non-infectious particles with the ‘core’ of one virus and the envelope glycoprotein of the study virus. PVs can be used as a fast, safe and effective screening tool for the prevalence of viruses in suspected infectees (www.viralpseudotypeunit.info). Intravacc supports a recent grant application from Dr Simon Scott, Dr Nigel Temperton (University of Kent) and Dr Edward Wright (University of Westminster) to develop a lyophilized, Ebola Pseudovirus- based Antibody neutralization kit for commercial use. By contributing to the project with its lyophilization and scale-up knowledge Intravacc aims to contribute to the fight against Ebola, a disease featured on the current WHO priority disease list.